Two Doses of Candidate TB Vaccine MVA85A in Antiretroviral Therapy (ART) Naïve Subjects Gives Comparable Immunogenicity to One Dose in ART+ Subjects

Tuberculosis (TB) is a global public health problem exacerbated by the HIV epidemic. Here we evaluate a candidate TB vaccine, MVA85A, in a Phase I study in HIV-infected adults in Senegal. 24 patients were enrolled: Group 1∶12, antiretroviral therapy (ART) naïve, adults, with CD4 counts >300 and H...

Descripción completa

Detalles Bibliográficos
Autores principales: Dieye, Tandakha N., NDiaye, Birahim P., Dieng, Alle B., Fall, Marema, Britain, Nathaniel, Vermaak, Samantha, Camara, Makhtar, Diop-Ndiaye, Halimatou, Ngom-Gueye, Ndeye Fatou, Diaw, Papa A., Toure-Kane, Coumba, Sow, Papa S., Mboup, Souleymane, McShane, Helen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3696007/
https://www.ncbi.nlm.nih.gov/pubmed/23840618
http://dx.doi.org/10.1371/journal.pone.0067177

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3696007/
https://www.ncbi.nlm.nih.gov/pubmed/23840618
http://dx.doi.org/10.1371/journal.pone.0067177

Ejemplares similares